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chronic non-cancer pain: an overview
of current evidencehronic non-cancer pain is highly prevalent in our Summary
communities and its optimal management is  Chronic non-cancer pain (lastingmore than 3months)
is highly prevalent in Australia (17% of males and
20% of females) and its optimal management is
crucial to the health and wellbeing of the community.
For5%of thepopulation, suchpain interferesmarkedly
with daily function. Part of the treatment for acute
non-cancer pain for many people will include opioid
analgesics at least for days toweeks. However, as pain
becomes chronic, evidence to support ongoing
prescription of opioids is lacking. There is increasing
pressure to ensure that prescribing opioid analgesics is
minimised to reduce not only the risk of dependence
and illicit diversion but also the potential harms asso-
ciated with tolerance, side effects and complications.
 Frameworks for considering opioid prescribing
include assessing suitability of the patient for opioids;
initiating a trial of therapy; and monitoring long term
use. There is limited evidence of the long term
efﬁcacy of opioids for chronic non-cancer pain, and
documented clinical consequences beyond addiction
include acceleration of loss of bone mineral density,
hypogonadism and an association with increased risk
of acute myocardial infarction.
 Careful clinical selection of patients can help
optimise the evidence-based use of opioids for
chronic non-cancer pain:
< only treat pain that has been as well deﬁned as
possible when non-opioid therapies have not been
effective;
< consider referral to specialist services for
assessment if doses are above 100mg oral
morphine equivalent per 24 hours or the duration
of therapy is longer than 4 weeks;
< limit prescribing to only one practitioner;
< seek an agreement with the patient for the
initiation and potential withdrawal of opioids if the
therapeutic trial is not effective.Ccrucial to the health and wellbeing of the com-
munity.1 Without good control of chronic pain, our
community faces a level of avoidable suffering that
cannot be justiﬁed, with costs of uncontrolled chronic
pain borne across society by individuals, health services
and businesses.2,3 At both the level of the individual
patient and the community, there needs to be focus on
using the best available evidence to assess and manage
this overwhelming problem. Part of the appropriate
treatment for many people will include opioid analgesics
for acute pain at least for days to weeks.4 Simultaneously
there is increasing pressure to ensure that prescribing of
opioid analgesics is minimised to reduce the risk of
dependence and illicit diversion. This is a difﬁcult balance
to strike, even with initiatives such as prescription drug
monitoring programs.5
This article provides a brief overview of the current
evidence to guide opioid use for chronic non-cancer pain
in general practice.
Chronic pain: deﬁnitions and epidemiology
The International Association for the Study of Pain de-
ﬁnes chronic pain as that which has persisted beyond
normal tissue healing time; by convention, this is usually
interpreted as pain that lasts for more than 3 months.6
Deﬁnitions for the duration of pain, intensity and level
of interference with daily activities vary around the
world. In the adult Australian population, pain has been
deﬁnedas chronic if experienceddaily for three of the past
6 months.1 Prevalence varies with the deﬁnition of
chronicity.7,8
Chronic non-cancer pain is a major health problem
around the world with prevalence rates as high as 33% of
the population in western populations.9 It is prevalent
across our communities, with up to 17.1% of men and
20.0% of women in Australia likely to experience the
problem.1 These rates are comparable to those found in
Denmark and Canada.10 Much higher rates have been
reported from the United Kingdom, where rates may be
as high as 46.5% of the population.11 Pain that interferes
markedlywith daily functioning has a rate in Australia of
5.0% of the population, with the strongest predictor being
a work-related injury in an adjusted model with an odds
ratio of 19.3 (95% CI 7.30e51.30; P< 0.001).12
The most frequently identiﬁed pains are those affecting
the lower back and from osteoarthritis.11 As expected, the
prevalence of pain increases with age, with some of the
highest rates seen in residential aged care facilities.13Chronic neuropathic pain is estimated to occur in one in
11 people.14
Chronic prescribing has been deﬁned as 90 days or more
of opioid prescribing in the past 120 days;15 this deﬁnition
is congruent with that of the International Association for
the Study of Pain.6
Current guidelines for safe prescribing of
opioids for chronic non-malignant pain
The twomost current and comprehensive evidence-based
guidelines for the use of opioids for chronic non-cancer
pain come from the United States and Canada.16,17 TheyMJA 204 (8) j 2 May 2016 305
Clinical focusshare the stated purpose of ensuring the appropriate
management of chronic non-cancer pain while minimis-
ing abuse of opioids.
The Canadian guideline is for all practitioners working
with chronic non-cancer pain, not just clinicians in
specialist pain practice (Box 1).17 Major domains in
considering such therapy are outlined in the document:
assessing patients for the suitability for opioids; initiating
a therapeutic trial of opioids and monitoring long term1 Roadmap for safe and effective use of opioids for chronic
non-cancer pain: Canadian guideline17
Reprinted with permission.u
306 MJA 204 (8) j 2 May 2016use. Sections are devoted to particular patient pop-
ulations. One recurring theme in the clinical recommen-
dations is to treat only “well deﬁned somatic or
neuropathic pain conditions when non-opioid alterna-
tives have failed”.17 Careneeds to be takenwhendeciding
to initiate or titrate opioids, especially in more vulnerable
populationswho have relevant comorbid conditions, and
great care is necessary if people requiremore than 200mg
of oral morphine equivalents. Another key theme is the
need for the clinicians involved in a patient’s care to
have clear lines of accountability with each other and
for agreed communication strategies among treating
clinicians.
Guidelines from the US stress that the use in the longer
term (more than 3 months) of opioids for chronic non-
cancer pain has little data to support the practice.16
However, in contrast to the Canadian guideline, the US
guidelines suggest that doses of greater than 91mg of
morphine equivalent should be treated with caution and
specialist advice sought. There is some evidence to sup-
port prescription drug monitoring programs and urine
drug testing as mechanisms to reduce abuse potential.
Less robust evidence supports a thorough patient
assessment, risk-screening tools, controlled-substance
agreements, careful dose titration, opioid dose ceilings,
and adherence to practice guidelines reduces the risk of
aberrant prescription drug-related behaviours.18
With respect to Australian recommendations, most
recently the National Prescribing Service (NPS) has
released a series of documents providing clinical advice
for health professionals engaged in the care of peoplewith
chronic pain. This includes a section titled “Best practice
opioid analgesic prescribing for chronic pain”, with the
Australian recommendations similar to those of the US
suggesting that daily doses above 100mg morphine
equivalent should be avoided. Further, recommendations
made by the NPS include the fact that when commencing
opioids, initial doses should be low with careful and su-
pervised titration.19 A summary of the NPS recommen-
dations is included in Box 2.Current prescribing trends in Australia
Australia continues to experience rising rates of opioid
prescription.20 Between 1992 and 2012, Australian opioid
dispensing episodes increased from 0.5 million pre-
scriptions to 7.5 million, with no evidence to suggest that
these ﬁgures are reaching a plateau.21 There has also been
an increase in thenumber of opioidpreparations available
(n¼ 241), including morphine (n¼ 87), fentanyl (n¼ 43)
and oxycodone (n¼ 37) as the largest three groups.21 The
indication on the Pharmaceutical Beneﬁts Scheme
generally includes use for chronic severe disabling pain
that is not responsive to non-opioids. The variation in
opioid prescribing across Australia has recently been
highlighted in the Australian Atlas of Healthcare
Variation published by the Australian Commission
on Safety and Quality in Health Care (http://www.
safetyandquality.gov.au/atlas).
2 Best practice opioid analgesic prescribing for
chronic pain: National Prescribing Service19
When trialling an opioid:
 limit the trial to 4 weeks and only after exploring all other
treatment options, both physical and psychological
 review weekly preferably with a family member
 encourage the use of a pain diary with a validated pain
assessment tool such as the Brief Pain Inventory
 assess for measureable improvements in quality of life
(sleep, mood, libido), function (activities) and pain scores
to gauge the effectiveness of opioids during the trial phase
 along with monitoring physical and mental condition,
monitor other key areas of function such as ﬁtness for
driving, work and other activities, and check for aberrant
drug-related behaviours
 avoid short-acting opioids
Dosing:
 start with low doses and titrate according to response and
adverse effects
 doses above the equivalent of 100 mg morphine per day
require reassessment, including specialist advice if possible
 exercise caution with older patients
Management plans and contracts:
 an opioid contract that summarises conditions of use along
with a management plan that outlines other activities can
help set realistic goals and expectations of behaviour while
undertaking an opioids trialu
3 Frequently encountered effects of opioids compared with placebo in
short term use24
No. of
trials
No. of
participants Side effect
Participants
experiencing side
effect
No. needed
to harm*Opioids Placebo
8 1114 Constipation 41% 11% 3.4
8 1114 Nausea 32% 12% 5.0
7 1022 Sedation 29% 10% 5.3
7 972 Vomiting 15% 3% 8.1
8 1114 Dizziness 20% 7% 8.2
6 981 Itching 15% 7% 1.3
7 677 Dry mouth 13% 9 e
*Short term; reverses immediately with cessation.u
Clinical focusThe overall increase in opioids in Australia likely reﬂects a
population that continues to grow rapidly in part because
of increasing life expectancywith chronic illnesses of ageing
often associated with pain, previous under-prescribing,
increasing incidence and survival from cancer, increased
numbers of preparations available, poor access to allied
health for non-pharmacological interventions, poor
undergraduate and postgraduate education about opioid
prescribing, aggressive marketing and the imperative for
health professionals to better manage pain.20
Clinical consequences of opioid use
Despite the prevalence of pain across the community,
overall chronic non-cancer pain generally remains
poorly treated, resulting in limitations in activity and
diminished quality of life. Although there are a variety
of strategies available to help manage chronic non-
cancer pain, for many people opioids are prescribed
long term. While some patients do achieve effective
analgesia, an estimated 40e70% of people with chronic
pain do not,22 with the balance towards those who
appear not to beneﬁt from opioids in the long term.23 It
is important to consider how the long term use is
balanced with the risk of short and long term adverse
effects of opioids.
Shorter term harms
Typically shorter term side effects are considered un-
pleasant but unlikely to lead to long term consequences(Box 3). Data from a systematic review suggest that for
every four patients commenced on opioids, at least one
person would experience at least one of these effects in a
1e8-week period.24
Longer term harms
Longer term harms may include physical and psycho-
logical issues and dependence. (Box 4) While most of the
adverse effects that occur when opioids are commenced
are expected to resolve rapidly,25 the adverse effects of
constipation, sedation or dizziness for some people may
not settle, all of which can cause signiﬁcant morbidity.
Older patients taking the equivalent of at least 50mg
of morphine daily have a twofold risk of sustaining a
fracture as a result of a fall.26
Opioids may contribute to acceleration of loss of bone
mineral density in the long term and to hypogonadism
because of their suppression of hypothalamic
gonadotrophin-releasing hormone. This can lead to
amenorrhea or oligomenorrhea in premenopausal
women and erectile dysfunction in men.27 There is also a
28% increase in the risk of myocardial infarction for
people taking opioids long term.28
Psychological impacts include higher rates of depression
after chronic opioid therapy is initiated in people who
were not previously depressed. In this same cohort,
higher rates of anxiety, lower self-efﬁcacy and a tendency
towards catastrophising were seen regardless of the
opioid doses.29
People who use opioids long term for chronic non-cancer
pain are at greater risk of misusing them, including
through psychological dependency and overdose. These
problems are prevalent in this cohort,with rates ofmisuse
(21e29%) and addiction (8e12%) a cause for grave
concern.30
The risk of sudden death due to opioids is ampliﬁed in the
context of concurrent benzodiazepine and/or alcohol
(mis)use.31MJA 204 (8) j 2 May 2016 307
4 Deﬁnitions of misuse, abuse and addiction30
Term Deﬁnition
Misuse Opioid use contrary to the directed or
prescribed pattern regardless of the presence
or absence of harm or adverse effects
Abuse Intentional use of the opioid for a non-medical
purpose such as euphoria or altering of one’s
state of consciousness
Addiction Pattern of continued use with experience of, or
demonstrated potential for harm with a
psychological dependence u
Clinical focusAside from the direct adverse effects of opioids, there
are several other potential negative consequences.
There is a subset of people who are not concurrently
using other agents such as alcohol, who are on modest
doses of opioids and not currently experiencing high
levels of pain, for whom driving is likely be to be
safe.32 In Australia, recommendations include the
suggestion that people should not drive if they feel
drowsy or impaired. Further, due to the persistent
miotic effects, driving at night is discouraged. If there
are concerns regarding capacity, a practical driving
assessment may be requested by health professionals
with the details as to how to achieve this in each state,
dependent on the local driver-licensing authority.33
Proper assessments of capacity are important given
that health service use increases with opioid use.
Higher rates of hospitalisations, emergency department
presentations and even unintentional death have been
recorded.31,34 The evidence that supports the beneﬁts
outweighing the risks of long term opioids for chronic
pain is very poor. There is real need for further
research to most clearly deﬁne which patients are most
likely to beneﬁt from opioids and what are the most
suitable precautions to safeguard them from harm.35
GPs’ attitudes to prescribing opioids for chronic
non-cancer pain
Despite the development of various guidance documents
for the safe and effective use of opioids,17,19,36,37 GPs
continue to be concerned about the risk of opioid depen-
dence and misuse for patients with chronic non-cancer
pain. There are also concerns expressed by GPs about
their capacity to manage the complex physical and psy-
chological needs of this patient cohort, and their role in
long term prescribing and the limitations of available
treatment approaches.38-41 Regional difference in opioid-
prescribing conﬁdence has been noted in a pan-European
online survey of primary care pain management prac-
tices.41 GPs in Norway (46%), Sweden (43%) and Poland
(37%) reported lower levels of opioid-prescribing conﬁ-
dence, which they attributed to fears of addiction and
adverse events.41 GPs in the UK, the Netherlands, France
and Italy were more conﬁdent about prescribing opioids
for patients with chronic non-cancer pain, which they
attributed to their experience and the therapeutic treat-
ment choices available.41308 MJA 204 (8) j 2 May 2016Opioid prescribing in primary care is complex because of
the need to optimise pain management while balancing
the risks of tolerance and addiction.37 Inappropriate
prescribing is more likely when patients are exposed to
repeated consultations that do not meet their needs and if
GPs feel powerless to negotiate an alternative plan of care
and set appropriate boundaries.38,42 If there is a perceived
paucity of treatment alternatives, opioid prescribing can
occur as a default decision.38 Variations in opioid pre-
scribing have previously been linked to GPs’ pain man-
agement training, experience and exposure to adverse
opiate-related events.43What can be done to reduce inappropriate
prescribing?
While there are opportunities to address inappropriate
prescribing at the system, provider and patient levels, one
of the most immediate changes could be achieved simply
bysupportingGPs tomanagepatients’ chronicnon-cancer
pain in accordance with recommended guidelines.39
Evidence-based guidelines provide GPs with an
evidence-based framework for the collaborative devel-
opment of a treatment plan with the patient.37 There are
also opportunities to strengthen safe opioid prescribing
by GPs for non-malignant pain through speciﬁc educa-
tion programs.44 Combining clinician education with an
opioid dose limitation practice policy45 and implement-
ing a practice policy of not providing repeat opioid pre-
scriptions or authorising a dose increase without a formal
medical reviewmay reduce the risk of inappropriate dose
escalation.38
High level evidence supports the use of methadone or
buprenorphine in patients with chronic non-cancer pain
who are addicted to opioids (high level evidence).17Indications to prescribe or not prescribe
chronic opioids
Only carefully selected patients should be considered
for long term opioids for chronic non-cancer pain that is
moderate to severe, has led to substantial negative im-
pacts on daily living and has failed all other analgesic
modalities and adequate allied health assessments.46
Any concerns about the prevalence of opioid prescrib-
ing must be balanced with ensuring that people with
opioid-responsive pain are adequately treated.47 Evi-
dence is slowly building to reﬁne prescribing guide-
lines, maximising beneﬁts and minimising harms.48
Many of the more routine pain problems such as
chronic back pain or chronic headaches are unlikely to
respond to opioids, in contrast to more severe and
physically disabling problems such as destructive
rheumatoid arthritis.34Managing aberrant patient behaviour
Aberrant behaviour related to prescription medications
includes any behaviour that suggests non-medical use of
a drug or evidence of addiction, such as drug-seeking
Clinical focusbehaviour, alternative routes of delivery, obtaining opi-
oids fromother sources orunsanctioneduse.39 Preventing
aberrant drug-related behaviour requires minimising the
riskof opioidmisusewhile optimising thebest evidenced-
based treatments for patients with chronic non-cancer
pain. In order to minimise harm, these patients require
an approach that is similar to other chronic illness in-
terventions, which includes appropriate non-
pharmacological and pharmacological approaches, and
an individualised evidence-based risk-mitigation plan to
optimise adherence.39 There is good evidence that deter-
mining the treatment goals of pain relief and improved
function can minimise the risk of aberrant behaviour.37
Prescribing tamper-resistant opioids currently offers the
highest level of prevention of opioid misuse.18
If a patientwith chronic non-cancer pain requests an early
opioid prescription, it is important to consider the possi-
bility that thepatientmayhavedeveloped tolerance to the
opioid, thus requiring a higher dose to maintain the same
level of pain control; developed physical dependence and
is experiencing early withdrawal symptoms; diverted
some or all of his or her opioids for ﬁnancial gain; or that a
third party may have diverted the prescribed opioids.49
Once aberrant behaviour has developed, management
becomes more complex and is likely to require a range of
responses including urgent referral to specialist services,
urine drug screening and other compliance monitoring,
treatment agreements, and patient education. High level
evidence suggests that when combined, these measures
can reduce substance misuse by 50%.50Ensuring adequate prescribing when indicated
Promoting and implementing the guidance offered by
recently updated guidelines and providing clinicians
with point-of-care resources can help to ensure adequate
and safe opioid prescribing for patients where opioids
are indicated. In patients with acute pain, both the US
and Canadian guidelines suggest that opioid therapy
may be initiated with low doses and short-acting drugs
with appropriate monitoring to provide effective relief
and avoid side effects.17,48 Further, the US guidelines
suggest that in well selected populations, chronic opioid
therapy may be continued ( 90 days), with continuous
adherence monitoring, in conjunction with or after fail-
ure of other modalities of treatments, with improvement
in physical and functional status and minimal adverse
effects.37
In addition to prescribing practices, greater emphasis on
chronic pain management during initial medical training
programs and access to point-of care pain management
guidelines is required to better support GPs to manage
opioid prescribing for people with non-malignant
pain.40,41 Improved access to allied health services when
pain is still acute is crucial if the prevalence of chronic,
non-cancer pain is to be reduced substantially.
Competing interests: No relevant disclosures.
Provenance: Commissioned; externally peer reviewed.n
ª 2016 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights reserved.
References are available online at www.mja.com.au.MJA 204 (8) j 2 May 2016 309
Clinical focus1 Blyth FM, March LM, Brnabic AJ, et al. Chronic pain in Australia:
a prevalence study. Pain 2001; 89: 127-134.
2 van Leeuwen MT, Blyth FM, March LM, et al. Chronic pain and
reduced work effectiveness: the hidden cost to Australian
employers. Eur J Pain 2006; 10: 161-166.
3 Blyth FM, March LM, Brnabic AJ, Cousins MJ. Chronic pain and
frequent use of health care. Pain 2004; 111: 51-58.
4 National Opioid Use Guideline Group. Canadian guideline for
safe and effective use of opioids for chronic non-cancer pain.
Hamilton, ON: NOUGG, 2010. http://nationalpaincentre.
mcmaster.ca/opioid/documents.html (accessed Mar 2016).
5 Islam MM, McRae IS. Real-time prescription drug monitoring
program in Australia: we should be ready. Drug Alcohol Rev
2015; 34: 344-345.
6 International Association for the Study of Pain. Classiﬁcation
of chronic pain. Pain 1986; Suppl 3: S1-S226.
7 Ricci JA, Stewart WF, Chee E, et al. Back pain exacerbations
and lost productive time costs in United States workers. Spine
2006; 31: 3052-3060.
8 Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain
in Europe: prevalence, impact on daily life, and treatment.
Eur J Pain 2006; 10: 287-333.
9 Marschall U, L’hoest HL, Radbruch L, Hauser W. Long-term
opioid therapy in chronic non-cancer pain in Germany. Eur J
Pain 2015; Oct 22. doi: 10.1002/ejp.802 [Epub ahead of print].
10 Eriksen J, Ekholm O, Sjogren P, Rasmussen NK. Development
of and recovery from longterm pain. A 6-year follow-up study
of a cross-section of the adult Danish population. Pain 2004;
108: 154-162.
11 Elliott AM, Smith BH, Penny KI, et al. The epidemiology
of chronic pain in the community. Lancet 1999; 354:
1248-1252.
12 Currow DC, Agar M, Plummer JL, Blyth FM, et al. Chronic pain in
South Australia — population levels that interfere extremely
with activities of daily living. Aust NZ J Public Health 2010; 34:
232-239.
13 Ramage-Morin PL. Medication use among senior Canadians.
Health Rep 2009; 20: 37-44.
14 Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of
chronic pain of predominantly neuropathic origin. Results from
a general population survey. J Pain 2006; 7: 281-289.
15 Jacobs SC, Son EK, Tat C, et al. Implementing an opioid risk
assessment telephone clinic: outcomes from a pharmacist-led
initiative in a large veterans health administration primary care
clinic, December 15, 2014-March 31, 2015. Subst Abus 2016; 37:
15-19.
16 Manchikanti L, Abdi S, Atluri S, et al. American Society of
Interventional Pain Physicians (ASIPP) guidelines for
responsible opioid prescribing in chronic non-cancer pain:
Part Ieevidence assessment. Pain Physician 2012; 15(3 Suppl):
S1-S65.
17 National Opioid Use Guideline Group. Canadian guideline for
safe and effective use of opioids for chronic non-cancer
pain. Part B: recommendations for practice. Hamilton, ON:
NOUGG, 2010 http://nationalpaincentre.mcmaster.ca/
documents/opioid_guideline_part_b_v5_6.pdf
(accessed Mar 2016).
18 Argoff CE, Kahan M, Sellers EM. Preventing and managing
aberrant drug-related behavior in primary care: systematic309.e1 MJA 204 (8) j 2 May 2016review of outcomes evidence. J Opioid Manage 2014; 10:
119-134.
19 NPS MedicineWise. Best practice opioid analgesic prescribing
for chronic pain. http://www.nps.org.au/conditions/nervous-
system-problems/pain/for-individuals/pain-conditions/
chronic-pain/for-health-professionals/opioid-medicines/best-
practice-prescribing (accessed Mar 2016).
20 Islam MM, McRrae IS, Mazumdar S et al. Prescription opioid
analgesics for pain management in Australia: twenty years of
dispensing. Int Med J 2015; Nov 25. doi: 10.1111/imj.12966 [Epub
ahead of print].
21 Blanch B, Pearson SA, Haber PS. An overview of the patterns
of prescription opioid use, costs and related harms in Australia.
Br J Clin Pharmacol 2014; 78: 1159-1166.
22 Reuben DB, Alvanzo AAH, Ashikaga T et al. National Institutes
of Health Pathways to Prevention Workshop: the role of
opioids in the treatment of chronic pain. Ann Intern Med 2015;
162: 295-300.
23 Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared
to placebo or other treatments for chronic low-back pain.
Cochrane Database Syst Rev 2013; (8): CD004959.
24 Kalsoa E, Edwards JE, Moore A, McQuay H. Opioids in chronic
non-cancer pain: systematic review. Pain 2004; 112: 372-380.
25 Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain.
BMJ 2015; 350: g6380.
26 Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid
use and dosage levels to fractures in older chronic pain
patients. J Gen Intern Med 2010; 25: 310-315.
27 Brennan MJ. The effect of opioid therapy on endocrine
function. Am J Med 2013; 126 (3 Suppl 1): S12-S8.
28 Chou R, Turner JA, Devine EB, et al. The effectiveness and risks
of long term opioid therapy for chronic pain: a systematic
review for a National Institutes of Health Pathways to
Prevention Workshop. Ann Intern Med 2015; 162: 276-286.
29 Ashworth J, Green DJ, Dunn KM, Jordan KP. Opioid use among
low back pain patients in primary care: is opioid prescription
associated with disability at 6-month follow-up? Pain 2013;
154: 1038-1044.
30 Vowles K, McEntee ML, Julnes PS et al. Rates of opioid misuse,
abuse and addiction in in chronic pain: a systematic review and
data synthesis. Pain 2015: 156: 569-576.
31 Calcaterra S, Glanz J, Binswanger IA. National trends in
pharmaceutical opioid related overdose deaths compared to
other substance related overdose deaths: 1999e2009. Drug
Alcohol Depend 2013: 131: 263-270.
32 Mailis-Gagnon A, Lakha SF, Furlan A, et al. Systematic review
of the quality and generalizability of studies on the effects of
opioids on driving and cognitive/psychomotor performance.
Clin J Pain 2012; 28: 542-555.
33 Austroads. Assessing ﬁtness to drive for commercial and
private vehicle drivers. March 2012 as amended up to June
2014. https://www.onlinepublications.austroads.com.au/
items/AP-G56-13 (accessed Mar 2016).
34 Franklin GM. Opioids for chronic noncancer pain. Neurology
2014; 83: 1277-1284.
35 Ballantyne JC. Assessing the prevalence of opioid misuse
abuse and addiction in chronic pain. Pain 2015; 156: 567-568.
36 Royal Australasian College of Physicians. Prescription opioid
policy: improving management of chronic non-malignant pain
Clinical focusand prevention of problems associated with prescription
opioid use. Sydney: RACP, 2008. http://www.fpm.anzca.edu.
au/resources/professional-documents/documents/Prescription
%20Opioid%20Policy.pdf (accessed Mar 2016).
37 Manchikanti L, Abdi S, Atluri CC, et al. American Society of
Interventional Pain Physicians (ASIPP) guidelines for
responsible opioid prescribing in chronic non-cancer pain: Part
2 e guidance. Pain Physician 2012; 15 (3 Suppl): S67-S116.
38 McCrorie C, Closs SJ, House A, et al. Understanding long-term
opioid prescribing for non-cancer pain in primary care: a
qualitative study. BMC Family Practice 2015; 16: 121.
39 Gordon A, Cone EJ, DePriest AZ, et al. Prescribing opioids for
chronic noncancer pain in primary care: risk assessment,
Postgrad Med 2014; 126: 159-166.
40 Blake H, Leighton P, van der Walt G, et al. Prescribing opioid
analgesics for chronic non-malignant pain in general
practice e a survey of attitudes and practice. Br J Pain 2015; 9:
225-232.
41 Johnson MJ, Bland JM, Oxberry SG, et al. Opioids for chronic
refractory breathlessness: patient predictors of beneﬁcial
response. Eur Respir J 2013; 42: 758-766.
42 Jamison RN, Scanlan E, Matthews ML, et al. Attitudes of
primary care practitioners in managing chronic pain patients
prescribed opioids for pain: a prospective longitudinal
controlled trial. Pain Med 2016; Jan 14. doi: 10.1111/pme.12871
[Epub ahead of print].43 Seamark D, Seamark C, Greaves C, Blake S. GPs prescribing
of strong opioid drugs for patients with chronic non-cancer
pain: a qualitative study. Br J Gen Pract 2013; 63:
e821-e828.
44 Alford DP, Zisblatt L, Ng P, et al. SCOPE of Pain: an evaluation
of an opioid risk evaluation and mitigation strategy continuing
education program. Pain Med 2015; Aug 25. doi: 10.1111/
pme.12878 [Epub ahead of print].
45 Weimar MB, Hartung DM, Ahmed S, Nicolaidis C. A chronic
opioid therapy dose reduction policy in primary care.
Subst Abus 2016; 37: 141-147.
46 Makris UE, Abram RC, Gurland B. Reid MC. Management
of persistent pain in the older patient: a clinical review.
JAMA 2014; 312: 825-836.
47 Duarte R, Raphael J. The pros and cons of long-term opioid
therapy. J Pain Palliat Care Pharmacother 2014; 28: 308-310.
48 Cheung CW, Qui Q, Choi SW. et al. Chronic opioid therapy for
chronic non-cancer pain: a review and comparison of
treatment guidelines. Pain Physician 2014; 17: 401-414.
49 Corsini E, Zacharoff KL. Deﬁnitions related to aberrant drug-
related behavior: is there correct terminology? PainEDU; 2011:
26; reviewed Feb 2014. https://www.painedu.org/articles_
timely.asp?ArticleNumber¼58 (accessed Mar 2016).
50 Manchikanti L, Manchukonda R, Damron KS, et al. Does
adherence monitoring reduce controlled substance abuse in
chronic pain patients? Pain Physician 2006; 9: 57-60.-MJA 204 (8) j 2 May 2016 309.e2
